Brief: Relief And Acer Therapeutics Sign License Agreement For Worldwide Development Of ACER-001

MindMaze Therapeutics Holding SA

22/03/2021 06:03

March 22 (Reuters) - RELIEF THERAPEUTICS HOLDING SA
 RLFB.S :
    * RELIEF AND ACER THERAPEUTICS SIGN COLLABORATION AND
LICENSE
AGREEMENT FOR WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION OF
ACER-001 FOR THE TREATMENT OF UCDS AND MSUD
    * RELIEF TO POTENTIALLY PAY ACER UP TO $36 MILLION AND
ROYALTIES
IN EXCHANGE FOR NET PROFIT SHARE AND TERRITORY RIGHTS
    * ACER-001 PRE-NDA MEETING WITH U.S. FDA SCHEDULED IN Q2
2021
    * ACER WILL RECEIVE AN APPROXIMATELY $10 MILLION CASH
PAYMENT
WITHIN 15 BUSINESS DAYS OF CLA EXECUTION
    * RELIEF WILL ALSO PAY ACER UP TO $20 MILLION IN U.S.
DEVELOPMENT
AND COMMERCIAL LAUNCH COSTS FOR UCDS AND MSUD INDICATIONS

Source text for Eikon:  ID:nEQ3khllca 
Further company coverage:  RLFB.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))